Limitations of the Harmony® Test
NIPT (non-invasive prenatal test) methods such as the Harmony® Test are used to detect chromosomal disorders (trisomies 21, 18, 13, and X/Y). What makes this method special is that it is non-invasive: only the mother’s blood is tested.
A NIPT method, however, cannot replace an ultrasound scan in the first trimester. First trimester screening and/or ultrasound scan towards the end of the first trimester can detect possible disorders in the fetal organs and is still strongly recommended.
Mosaicism, partial trisomies or translocations
cffDNA-based NIPT methods are not yet able to detect chromosomal mosaicism, partial trisomies or translocations.
Proportion of cell-free fetal DNA
In order to ensure the detection of a chromosomal disorder in the unborn child, the proportion of cell-free fetal DNA (cffDNA) (“Fetal Fraction”) in the mother’s blood must be at least 4% 1. The Harmony® Test can be performed after pregnancy week 10+0 because the proportion of fetal DNA in the mother’s blood rises with the length of the pregnancy (see figure below).
There is also a correlation between the mother’s weight and the “Fetal Fraction”: the higher the mother’s weight, the lower the proportion of fetal DNA in the mother’s blood.
For every Harmony® Test the “Fetal Fraction” is measured. If the Fetal Fraction is below 4%, the test cannot be evaluated. The sender will be informed that a new blood sample should be submitted at a slightly later date (approximately after 3 weeks). The patient will not be charged for tests that cannot be evaluated.
Secret egg donation
The Harmony® Test can be performed irrespective of the manner of conception or origin of the ovum. Due to specialized bioinformatics analyses, however, by filling out the test requisition form it must be informed about an egg donation when the test is requested. If an egg donation is kept secret, the Harmony® Test is not able to deliver a result.
Vanishing twin
In a vanishing twin situation residues of placental tissue could influence the Harmony® Test towards false-positive as well as false-negative results. Therefore the Harmony® Test can not be performed.
Transplant, malignancy or maternal aneuploidy
The Harmony® Test is not validated for use in pregnancies with maternal aneuploidy, transplant or malignancy.
X/Y analysis and DiGeorge syndrome analysis in Twins
The Harmony® Test can be used in twin pregnancies. However, it is not yet possible to detect X or Y sex chromosomal anomalies (e.g. Turner or Klinefelter syndrom) or the DiGeorge syndrome in twin pregnancies.
The detection rate in twins is not quite as high as for singleton pregnancies. In two recent studies 3, 4 a total of 24 of the 26 trisomy cases were detected (detection rate approx. 92%).
The table below provides an overview of which Harmony® Test options are appropriate for which pregnancies.
| Harmony® Test |  |
|
 |
|
| Harmony® with with X/Y analysis | |
|
|
|
| DiGeorge syndrome | |
|
|
|
| sex determination | |
|
|
|
Limitations of the Harmony® Test
In a very small number of cases (1.6%), the Harmony® Test cannot be performed successfully. This is usually because the content of cell-free fetal DNA (cffDNA) in the blood is too low for a result to be obtained. In such a case we recommend blood be taken again at a later point and the Harmony® Test be repeated. The majority of cases can be processed successfully after a second blood sample is submitted. Only approximately 0.6% of all cases are unsuccessful after the second attempt. In these cases, a decision has to be made with the patient as to whether further first trimester screening or possibly an invasive procedure should be performed.
Other reasons for test failure include the existence of an egg donation about which was not informed. With the subsequent information of an egg donation, the Harmony® Test can usually obtain a result.
The demise of one fetus in a twin pregnancy (“vanishing twin”), transplantations or previously unknown (and in general benign) maternal chromosomal disorders can also lead to a failure of the test. For these cases the Harmony Test is not validated and should not be performed or repeated.
Confirmation of the positive result through an invasive diagnostic method
Despite significant improvements over former non-invasive tests, the detection rate for the Harmony® Prenatal Test is not 100%. False-positive results may occure. Therefore the Harmony® Prenatal Test should be regarded as a screening test and not a diagnostic test. A positive (abnormal) result should therefore always be confirmed by a second, diagnostic method (chorionic villus sampling or amniotic puncture) with a subsequent chromosome analysis.
False-negative results are also possible. This is more common for trisomy 13 and the analysis of DiGeorge syndrome (Microdeletion 22q11.2).
The Harmony® Test detects around 30 out of 32 trisomy 13 cases in its current version. A summary of all previous studies on trisomy 13 revealed an average detection rate of 93,8% 5. Trisomy 13 is, however, relatively easy to detect in an ultrasound scan during first trimester screening.
The Harmony® Test is able to detect 75% of all 22q11.2 microdeletions, including those smaller than 3 Mb at a false-positive rate of 0.5% 6.
- Ashoor G, Poon L, Syngelaki A, Mosimann B, Nicolaides KH. Fetal Fraction in Maternal Plasma Cell-Free DNA at 11–13 Weeks’ Gestation: Effect of Maternal and Fetal Factors. Fetal Diagn Ther 2012;31:237-243. ↩
- Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013 Jul;33(7):662-6. doi: 10.1002/pd.4119. Epub 2013 May 9. ↩
- Bevilacqua E, Gil MM, Nicolaides KH, Ordoñez E, Cirigliano V, Dierickx H, Willems PJ, Jani JC. Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies. Ultrasound Obstet Gynecol. 2015 Jan;45(1):61-6. doi: 10.1002/uog.14690. Epub 2014 Dec 4. ↩
- Gil MM, Quezada MS, Bregant B, Syngelaki A, Nicolaides KH. Cell-free DNA analysis for trisomy risk assessment in first-trimester twin pregnancies. Fetal Diagn Ther. 2014;35(3):204-11. doi: 10.1159/000356495. Epub 2013 Nov 15. ↩
- Stokowski R, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ.: Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies. Prenat Diagn. 2015 Sep 1 ↩
- Schmid M et al. Prenatal Screening for 22q11.2 Deletion Using a Targeted Microarray-Based Cell-Free DNA Test.Fetal Diagn Ther. 2017 Nov 8, E-pub ahead of print ↩